The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > COMMENTARY
COMMENTARY
- How to Eliminate Concerns about Safety of Liovel
October 4, 2010
- Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
September 20, 2010
- Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
- Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
- Industry Needs to Form Consensus on Premium with Med. Institutions
July 26, 2010
- Japan Should Promote Personalized Cancer Treatment
July 26, 2010
- METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
- How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
- Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
- PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
- Taiyo Needs to Restart from Scratch
April 19, 2010
- Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
- Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
- New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
- Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
- Korosho Moves to Change Its Vaccine Policy
February 22, 2010
- Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
- Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
- New Pricing System to Make e-Detailing More Important
February 1, 2010
- Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
November 30, 2009
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…